Global Depression Drugs Market 2015-2019

2015-06-10
Price :
Published : Jun-2015
No. of Pages : 107

According to the WHO, depression is a common mental disorder that contributes significantly to the global burden of disease. It affects people across communities worldwide. It is characterized by sadness, loss of interest or pleasure, feelings of guilt or low self-worth, disturbed sleep or appetite, feelings of tiredness, and poor concentration. Depression can be roughly categorized into six different types. An individual with severe depression can have suicidal thoughts and behaviors. According to a 2012 estimate by the WHO, about 3,000 suicides take place each day, resulting in more than a million deaths each year. Depression can be recurrent and can be severely debilitating. Patients with mild depression can be treated with medications, but in cases of moderate or severe depression, the patient needs both medication and professional psychotherapy in the form of counseling. According to a 2008 report by the WHO, depression affects men and women equally, but women are more likely to be affected by depression than men. According to the CDC, depression can lead to many adverse behaviors in an individual such as alcoholism, smoking, and sleep disturbance. According to the CDC factsheet, in the US, one in every 10 individuals is affected by depression. According to the NIMH in the US, major depressive disorder is one of the most debilitating disorders in the US and affects about 14.80 million adults aged 18 years and above.

The analysts forecast the global depression drugs market to grow at a CAGR of 5.25% over the period 2014-2019.

Covered in this report

This report covers the present scenario and the growth prospects of the global depression drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used for the treatment of depression. The global depression drugs market is segmented based on the mechanism of action of the drugs used to treat depression, as mentioned below:

  • Tricyclic antidepressants
  • Serotonin-norepinephrine reuptake inhibitors
  • Selective serotonin reuptake inhibitors
  • Monoamine oxidase inhibitors
  • Others

The report, Global Depression Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC; it also covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • Actavis
  • Bristol-Myers Squibb
  • Eli Lilly
  • GlaxoSmithKline
  • Pfizer

Other Prominent Vendors

  • Abbott Laboratories
  • Addex Therapeutics
  • Alkermes
  • AstraZeneca
  • Aurobindo Pharma
  • Avanir Pharmaceuticals
  • Cerecor
  • Chugai Pharmaceutical
  • Dart NeuroScience
  • Dr. Reddy’s Laboratories
  • Edgemont Pharmaceuticals
  • E-Therapeutics
  • Euthymics
  • Evotec
  • F. Hoffmann-La Roche
  • Fabre Kramer
  • Gedeon Richter
  • H. Lundbeck
  • Intra-Cellular Therapies
  • Janssen Pharmaceuticals
  • Lupin
  • Luye Pharma
  • MSI Methylation Sciences
  • Naurex
  • Neuralstem
  • Novartis
  • Opko Health
  • Otsuka Pharmaceutical
  • Pierre Fabre
  • Shire
  • SK Biopharmaceuticals
  • Somerset Pharmaceuticals
  • Sun Pharmaceutical
  • Sunovion Pharmaceuticals
  • Suven
  • Takeda Pharmaceutical
  • Teva Pharmaceutical
  • Torrent Pharmaceuticals
  • Valeant Pharmaceuticals

Market Driver

  • Rise in patient population
  • For a full, detailed list, view our report

Market Challenge

  • Threat of expiry of patents
  • For a full, detailed list, view our report

Market Trend

  • Growing public awareness
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
Filed in: Pharmaceutical
Publisher : Technavio
More Reports
Title Price Buy Now

ForeSights: Salt Therapy – An old-fashioned, non-invasive treatment enjoying a renaissance as a new health and wellness solution

ForeSights: Salt Therapy - An old-fashioned, non-invasive treatment enjoying a renaissance as a new health and wellness solution Summary Salt therapy is a non-invasive treatment that uses aerated salt or a salt bath to deliver health and wellness benefits. It comes in two forms: dry salt therapy (halotherapy) and wet salt therapy (flotation therapy). Both forms of salt therapy are claimed to promote relaxation and rejuvenation. Salt therapy is an old-fashioned, drug-free treatment leveraging the claimed natural antibacterial and anti-inflammatory properties of salt that capitalizes on growing interest in complementary and alternative medicine. Scope - Dry salt therapy (halotherapy) takes mineral-rich salt and grinds it into a fine powder that is dispensed into the air to cre......
$495

EpiCast Report: Osteoarthritis – Epidemiology Forecast to 2026

EpiCast Report: Osteoarthritis - Epidemiology Forecast to 2026 Summary Osteoarthritis (OA) is a gradually progressive joint disease that is typically seen in middle-aged to elderly people. According to the American College of Rheumatology (ACR), OA is the most common cause of disability in the elderly. The most commonly affected joints are the knee, hip, hand, and spine. It is characterized by breakdown of the cartilage, bony changes of the joints, deterioration of tendons and ligaments, and various degrees of inflammation of the joint lining. To forecast the total prevalent cases (radiographic), total prevalent cases (symptomatic), and diagnosed prevalent cases (symptomatic) of hand OA, knee OA, and hip OA in the 7MM, GlobalData epidemiologists selected nationally representative,......
$3995

Hemangiomas Global Clinical Trials Review, H2, 2017

Hemangiomas Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hemangiomas Global Clinical Trials Review, H2, 2017" provides an overview of Hemangiomas clinical trials scenario. This report provides top line data relating to the clinical trials on Hemangiomas. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical tri......
$2500

Hematological Tumor Global Clinical Trials Review, H2, 2017

Hematological Tumor Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hematological Tumor Global Clinical Trials Review, H2, 2017" provides an overview of Hematological Tumor clinical trials scenario. This report provides top line data relating to the clinical trials on Hematological Tumor. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinic......
$2500

Hematoma Global Clinical Trials Review, H2, 2017

Hematoma Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hematoma Global Clinical Trials Review, H2, 2017" provides an overview of Hematoma clinical trials scenario. This report provides top line data relating to the clinical trials on Hematoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are coll......
$2500

Hematopoietic Stem Cell Transplantation Global Clinical Trials Review, H2, 2017

Hematopoietic Stem Cell Transplantation Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hematopoietic Stem Cell Transplantation Global Clinical Trials Review, H2, 2017" provides an overview of Hematopoietic Stem Cell Transplantation clinical trials scenario. This report provides top line data relating to the clinical trials on Hematopoietic Stem Cell Transplantation. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Repo......
$2500

Partnerships, Licensing, Investments and M&A Deals and Trends for July 2017 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for July 2017 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for July 2017 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in July 2017. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provide......
$1000

Hemiplegia Global Clinical Trials Review, H2, 2017

Hemiplegia Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hemiplegia Global Clinical Trials Review, H2, 2017" provides an overview of Hemiplegia clinical trials scenario. This report provides top line data relating to the clinical trials on Hemiplegia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials ......
$2500

Heart Transplant Rejection Global Clinical Trials Review, H2, 2017

Heart Transplant Rejection Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Heart Transplant Rejection Global Clinical Trials Review, H2, 2017" provides an overview of Heart Transplant Rejection clinical trials scenario. This report provides top line data relating to the clinical trials on Heart Transplant Rejection. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary dat......
$2500

Heart Valve Disease Global Clinical Trials Review, H2, 2017

Heart Valve Disease Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Heart Valve Disease Global Clinical Trials Review, H2, 2017" provides an overview of Heart Valve Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Heart Valve Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinic......
$2500